PE‐Erl consisted of NEK7, SLCO3A1, RELB, FRMD4A, HSD17B2, CDK6, PALM, IL1RN, SMYD1, BAG2, GNG3 and SULT1E1 and was used to predict chemotherapy response in NSCLC patients. This evidence concerns the gene RELB and non-small cell lung carcinoma.